Skip to content
2000
Volume 31, Issue 7
  • ISSN: 0929-8665
  • E-ISSN: 1875-5305
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Background

Osteosarcoma (OS) is the leading cancer-associated mortality in childhood and adolescence. Increasing evidence has demonstrated the key function of microRNAs (miRNAs) in OS development and chemoresistance. Among them, miRNA-605-3p acted as an important tumor suppressor and was frequently down-regulated in multiple cancers. However, the function of miR-650-3p in OS has not been reported.

Objective

The aim of this work is to explore the novel role of miR-605-3p in osteosarcoma and its possible involvement in OS chemotherapy resistance.

Methods

The expression levels of miR-605-3p in OS tissues and cells were assessed by reverse transcription quantitative PCR (RT-qPCR). The relevance of miR-605-3p with the prognosis of OS patients was determined by the Kaplan-Meier analysis. Additionally, the influence of miR-605-3p on OS cell growth was analyzed using the cell counting kit-8, colony formation assay, and flow cytometry. The mRNA and protein expression of RAF1 were detected by RT-qPCR and western blot. The binding of miR-605-3p with the 3’-UTR of RAF1 was confirmed by dual-luciferase reporter assay.

Results

Our results showed that miR-605-3p was markedly decreased in OS tissues and cells. A lower level of miR-605-3p was strongly correlated with lymph node metastasis and poor 5-year overall survival rate of OS patients. assay found that miR-605-3p suppressed OS cell proliferation and promoted cell apoptosis. Mechanistically, the proto-oncogene RAF1 was seen as a target of miR-605-3p and strongly suppressed by miR-605-3p in OS cells. Restoration of RAF1 markedly eliminated the inhibitory effect of miR-605-3p on OS progression, suggesting RAF1 as a key mediator of miR-605-3p. Consistent with the decreased level of RAF1, miR-605-3p suppressed the activation of both MEK and ERK in OS cells, which are the targets of RAF1. Moreover, lower levels of miR-605-3p were found in chemoresistant OS patients, and down-regulated miR-605-3p increased the resistance of OS cells to therapeutic agents.

Conclusion

Our data revealed that miR-605-3p serves as a tumor suppressor gene by regulating RAF1 and increasing the chemosensitivity of OS cells, which provided the novel working mechanism of miR-605-3p in OS. Engineering stable nanovesicles that could efficiently deliver miR-605-3p with therapeutic activity into tumors could be a promising therapeutic approach for the treatment of OS.

© 2024 Bentham Science Publishers
© 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/ppl/10.2174/0109298665314658240712051206
2024-07-01
2025-07-15

  • From This Site

    /content/journals/ppl/10.2174/0109298665314658240712051206
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
The full text of this item is not currently available.

References

  1. GazouliI. KyriazoglouA. KotsantisI. AnastasiouM. PantazopoulosA. PrevezanouM. ChatzidakisI. KavourakisG. EconomopoulouP. KontogeorgakosV. PapagelopoulosP. PsyrriA. Systematic review of recurrent osteosarcoma systemic therapy.Cancers2021138175710.3390/cancers13081757 33917001
     [Google Scholar]
  2. ZhaoX. WuQ. GongX. LiuJ. MaY. Osteosarcoma: A review of current and future therapeutic approaches.Biomed. Eng. Online20212012410.1186/s12938‑021‑00860‑0 33653371
     [Google Scholar]
  3. JiangZ.Y. LiuJ.B. WangX.F. MaY.S. FuD. Current status and prospects of clinical treatment of osteosarcoma.Technol. Cancer Res. Treat.2022211533033822112469610.1177/15330338221124696 36128851
     [Google Scholar]
  4. StefaniG. SlackF.J. Small non-coding RNAs in animal development.Nat. Rev. Mol. Cell Biol.20089321923010.1038/nrm2347 18270516
     [Google Scholar]
  5. BartelD.P. MicroRNAs.Cell2004116228129710.1016/S0092‑8674(04)00045‑5 14744438
     [Google Scholar]
  6. FabianM.R. SonenbergN. FilipowiczW. Regulation of mRNA translation and stability by microRNAs.Annu. Rev. Biochem.201079135137910.1146/annurev‑biochem‑060308‑103103 20533884
     [Google Scholar]
  7. FasoulakisZ. DaskalakisG. DiakosavvasM. PapapanagiotouI. TheodoraM. BourazanA. MicroRNAs determining carcinogenesis by regulating oncogenes and tumor suppressor genes during cell cycle.MicroRNA201992829210.2174/2211536608666190919161849 31538910
     [Google Scholar]
  8. FaraziT.A. SpitzerJ.I. MorozovP. TuschlT. miRNAs in human cancer.J. Pathol.2011223210211510.1002/path.2806 21125669
     [Google Scholar]
  9. AsadzadehZ. MansooriB. MohammadiA. AghajaniM. Haji-AsgarzadehK. SafarzadehE. microRNAs in cancer stem cells: Biology, pathways, and therapeutic opportunities.J. Cell. Physiol.20182347100021001710.1002/jcp.27885 30537109
     [Google Scholar]
  10. DongZ. LiaoZ. HeY. WuC. MengZ. QinB. XuG. LiZ. SunT. WenY. LiG. Advances in the biological functions and mechanisms of miRNAs in the development of osteosarcoma.Technol. Cancer Res. Treat.2022211533033822111738610.1177/15330338221117386 35950243
     [Google Scholar]
  11. FanL. ZhongZ. LinY. LiJ. Non-coding RNAs as potential biomarkers in osteosarcoma.Front. Genet.202213102847710.3389/fgene.2022.1028477 36338952
     [Google Scholar]
  12. LiuJ. ShangG. The roles of noncoding rnas in the development of osteosarcoma stem cells and potential therapeutic targets.Front. Cell Dev. Biol.20221077303810.3389/fcell.2022.773038 35252166
     [Google Scholar]
  13. ScuderiS.A. CalabreseG. PaternitiI. CampoloM. LanzaM. CapraA.P. PantaleoL. MunaòS. ColarossiL. ForteS. CuzzocreaS. EspositoE. The biological function of MicroRNAs in bone tumors.Int. J. Mol. Sci.2022234234810.3390/ijms23042348 35216464
     [Google Scholar]
  14. SoghliN. FernsG.A. SadeghsoltaniF. QujeqD. YousefiT. Vaghari-TabariM. MicroRNAs and osteosarcoma: Potential targets for inhibiting metastasis and increasing chemosensitivity.Biochem. Pharmacol.202220111509410.1016/j.bcp.2022.115094 35588853
     [Google Scholar]
  15. PanM.Z. SongY.L. GaoF. MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2.Eur. Rev. Med. Pharmacol. Sci.201923208795880510.26355/eurrev_201910_19274 31696466
     [Google Scholar]
  16. HuY.L. FengY. ChenY.Y. LiuJ.Z. SuY. LiP. HuangH. MaoQ.S. XueW.J. SNHG16/miR‐605‐3p/TRAF6/NF‐κB feedback loop regulates hepatocellular carcinoma metastasis.J. Cell. Mol. Med.202024137637765110.1111/jcmm.15399 32436333
     [Google Scholar]
  17. PanM.Z. SongY.L. GaoF. MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2.Eur. Rev. Med. Pharmacol. Sci.2021255215610.26355/eurrev_202103_25197 33755945
     [Google Scholar]
  18. SuY.Z. CuiM.F. DuJ. SongB. LncRNA DCST1-AS1 regulated cell proliferation, migration, invasion and apoptosis in gastric cancer by targeting miR-605-3p.Eur. Rev. Med. Pharmacol. Sci.20202431158116710.26355/eurrev_202002_20167 32096164
     [Google Scholar]
  19. LiuN. HuG. WangH. WangY. GuoZ. LncRNA BLACAT1 regulates VASP expression via binding to miR‐605‐3p and promotes giloma development.J. Cell. Physiol.201923412221442215210.1002/jcp.28778 31093978
     [Google Scholar]
  20. RosicG. Cancer signaling, cell/gene therapy, diagnosis and role of nanobiomaterials.Adv. Biol. Earth Sci.20249Special Issue113410.62476/abes9s11
     [Google Scholar]
  21. KhalilovR.K. Future prospects of biomaterials in nanomedicine.Adv. Biol. Earth Sci.2024951010.62476/abes.9s5
     [Google Scholar]
  22. HuseynovE. Novel nanomaterials for hepatobiliary diseases treatment and future perspectives.Adv. Biol. Earth Sci.20249819110.62476/abes9s81
     [Google Scholar]
  23. MiwaW. YasudaJ. YashimaK. MakinoR. SekiyaT. Absence of activating mutations of the RAF1 protooncogene in human lung cancer.Biol. Chem. Hoppe Seyler19943751070571010.1515/bchm3.1994.375.10.705 7888083
     [Google Scholar]
  24. BorovskiT. VellingaT.T. LaoukiliJ. SantoE.E. FatraiS. van SchelvenS. VerheemA. MarvinD.L. UbinkI. Borel RinkesI.H.M. KranenburgO. Inhibition of RAF1 kinase activity restores apicobasal polarity and impairs tumour growth in human colorectal cancer.Gut20176661106111510.1136/gutjnl‑2016‑311547 27670374
     [Google Scholar]
  25. TianH. YinL. DingK. XiaY.Y. WangX.H. WuJ.Z. HeX. Raf1 is a prognostic factor for progression in patients with non small cell lung cancer after radiotherapy.Oncol. Rep.20183941966197410.3892/or.2018.6277 29484414
     [Google Scholar]
  26. ZhangL. PattanayakA. LiW. KoH.K. FowlerG. GordonR. A multi-functional therapy approach for cancer: Targeting Raf1- mediated inhibition of cell motility, growth and interaction with the microenvironment.Mol. Cancer Ther.2019191395110.1158/1535‑7163.MCT‑19‑0222 31582531
     [Google Scholar]
  27. YangG. WuY. WanR. SangH. LiuH. HuangW. The role of non coding RNAs in the regulation, diagnosis, prognosis and treatment of osteosarcoma (Review).Int. J. Oncol.20215936910.3892/ijo.2021.5249 34296296
     [Google Scholar]
  28. ZengZ. ZhouW. DuanL. ZhangJ. LuX. JinL. YuY. Circular RNA circ‐VANGL1 as a competing endogenous RNA contributes to bladder cancer progression by regulating miR‐605‐3p/VANGL1 pathway.J. Cell. Physiol.201923443887389610.1002/jcp.27162 30146736
     [Google Scholar]
  29. ChenL. WangQ. WangG. WangH. HuangY. LiuX. CaiX. miR‐16 inhibits cell proliferation by targeting IGF1R and the Raf1–MEK1/2–ERK1/2 pathway in osteosarcoma.FEBS Lett.201358791366137210.1016/j.febslet.2013.03.007 23507142
     [Google Scholar]
  30. ChaiJ. WangS. HanD. DongW. XieC. GuoH. MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase.Tumour Biol.20153621313132110.1007/s13277‑014‑2766‑3 25355599
     [Google Scholar]
  31. WangT.H. HsuehC. ChenC.C. LiW.S. YehC.T. LianJ.H. ChangJ.L. ChenC.Y. Melatonin inhibits the progression of hepatocellular carcinoma through MicroRNA Let7i-3p mediated RAF1 reduction.Int. J. Mol. Sci.2018199268710.3390/ijms19092687 30201903
     [Google Scholar]
  32. WangF. Jiang, ; Sun, Q.; Yan, ; Wang, ; Fu, ; Liu, ; Hu, miR-195 is a key regulator of Raf1 in thyroid cancer.OncoTargets Ther.201583021302810.2147/OTT.S90710 26527888
     [Google Scholar]
  33. TaoL. ZhangC.Y. GuoL. LiX. HanN.N. ZhouQ. LiuZ.L. Retracted: MicroRNA‐497 accelerates apoptosis while inhibiting proliferation, migration, and invasion through negative regulation of the MAPK/ERK signaling pathway via RAF‐1.J. Cell. Physiol.2018233106578658810.1002/jcp.26272 29150931
     [Google Scholar]
/content/journals/ppl/10.2174/0109298665314658240712051206
Loading
MicroRNA-605-3p Inhibited the Growth and Chemoresistance of Osteosarcoma Cells via Negatively Modulating RAF1
PPL 31, 559 (2024); https://doi.org/10.2174/0109298665314658240712051206
/content/journals/ppl/10.2174/0109298665314658240712051206
/content/journals/ppl/10.2174/0109298665314658240712051206
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Research Article
Keyword(s): ERK; MEK; miR-605-3p; OS cells; osteosarcoma; RAF1

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test